Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation

International Journal of Pharmaceutics

Volumn 422, Issue 1-2, 2012, Pages 179-184

  Paliwal, Rishi ^a   Paliwal, Shivani R ^a   Agrawal, Govind P ^b   Vyas, Suresh P ^a  

^a Drug Delivery Research Laboratory   (India)

^b Pharmaceutics Laboratory   (India)

Author keywords

Bioavailability; Low molecular weight heparin; Nanoparticles; Oral delivery; Trimethyl chitosan

Indexed keywords

CHITOSAN; LOW MOLECULAR WEIGHT HEPARIN; NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MAXIMUM PLASMA CONCENTRATION; METHYLATION; MORPHOLOGY; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 84655167657     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.10.048     Document Type: Article

References (17)

1. E. Arbit, M. Goldberg, I. Gomez-Orellana, and S. Majuru Oral heparin: status review Thromb. J. 10 2006 4 6
2. P. Calvo, C. Remuñan-López, J.L. Vila-Jato, and M.J. Alonso Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines Pharm Res. 14 1997 1431 1436 (Pubitemid 27481075)
3. T. Chandy, G.H. Rao, R.F. Wilson, and G.S. Das Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis Drug Deliv. 9 2002 87 96 (Pubitemid 34606532)
4. M. Goldberg, and I. Gomez-Orellana Challenges for the oral delivery of macromolecules Nat. Rev. Drug Discov. 2 2003 289 295 (Pubitemid 37361687)
5. V. Hoffart, A. Lamprecht, P. Maincent, T. Lecompte, C. Vigneron, and N. Ubrich Oral bioavailability of a low molecular weight heparin using a polymeric delivery system J. Controlled Release 113 2006 38 42 (Pubitemid 43818166)
6. L. Illum Chitosan and its use as a pharmaceutical excipient Pharm. Res. 15 1998 1326 1331 (Pubitemid 28427917)
7. Y. Jiao, N. Ubrich, M. Marchand-Arvier, C. Vigneron, M. Hoffman, T. Lecompte, and P. Maincent In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits Circulation 105 2002 230 235 (Pubitemid 34084324)
8. C.E. Kast, D. Guggi, N. Langoth, and A. Bernkop-Schnürch Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil Pharm. Res. 20 2003 931 936 (Pubitemid 36628442)
9. S.S. Lanke, S.G. Gayakwad, J.G. Strom, and M.J. D'souza Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system J. Microencapsul. 26 2009 493 500
10. N.A. Motlekar, and B.B. Youan The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins J. Controlled Release 113 2006 91 101 (Pubitemid 43928148)
11. R. Paliwal, S.R. Paliwal, G.P. Agrawal, and S.P. Vyas Biomimetic solid lipid nanoparticles for oral bioavailability enhancement of low molecular weight heparin and its lipid conjugates: in vitro and in vivo evaluation Mol. Pharm. 8 2011 1314 1321
12. R. Paliwal, S.R. Paliwal, G.P. Agrawal, and S.P. Vyas Recent advances in search of oral heparin therapeutics Med. Res. Rev. 2011 10.1002/med.20217
13. A. Rawat, Q.H. Majumder, and F. Ahsan Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation J. Controlled Release 128 2008 224 232
14. A.B. Sieval, M. Thanou, A.F. Kotze, J.C. Verhoef, J. Brussee, and J.E. Junginger Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride Carbohydr. Polym. 36 1998 157 165 (Pubitemid 128399589)
15. M.M. Thanou, A.F. Kotzé, T. Scharringhausen, H.L. Luessen, A.G. de Boer, J.C. Verhoef, and H.E. Junginger Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers J. Controlled Release 64 2000 15 25 (Pubitemid 30035304)
16. S. Wadhwa, R. Paliwal, S.R. Paliwal, and S.P. Vyas Chitosan and its role in ocular therapeutics Mini. Rev. Med. Chem. 9 2009 1639 1647
17. S. Wadhwa, R. Paliwal, S.R. Paliwal, and S.P. Vyas Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation J. Drug Target 18 2010 292 302